On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25$190 million.The company reported an adjusted EPS loss of $(2.32), more than double the$(1.05) reported a year ago, missing the consensus of $(0.94).Revenues from Narcan (naloxone HCl) Nasal Spray decreased 10$120 million, primarily driven by an unfavorable price and volume mix in 2024 to U.S. public interest channels and lower Canadian market sales, partia ...